Search

Showing "11155" results for ""

CROI: Atazanavir/ritonavir joins other boosted PIs as potential single-class maintenance regimen

CROI: HIV subtype D causes disease more rapidly than HIV-1 subtype A in Uganda

CROI: CD4-guided treatment interruptions unsafe, SMART study concludes

CROI: Merck integrase inhibitor strong in highly treatment-experienced patients

CROI: Side-effects, especially neuropathy and rash, common but rarely severe in two studies of African patients on antiretroviral therapy

CROI: New Gilead integrase inhibitor GS-9137 displays potent activity

CROI: Heart attack risk elevated by protease inhibitor treatment but not NNRTIs

CROI: Tenofovir and kidney toxicity - low rates seen, but some groups may be more vulnerable

CROI News Feature: Experts divided over the future of treatment interruptions

CROI: Study reveals widespread misunderstandings about post-exposure prophylaxis among US doctors

CROI: Greater declines in TB incidence observed with long-term antiretroviral therapy

CROI: Study fuels debate on role of GB virus C in HIV disease

CROI: Capsaicin patch helps relieve neuropathy

CROI: Fish oil and fibrate combination reduces blood fats in HIV patients

CROI: Disappointment for glitazones, metformin and testosterone for body fat changes

CROI: Risk of new illnesses declines sharply after first two months on treatment in resource-limited settings

CROI: TB rates skyrocketing in Western Cape township — most infectious cases associated with HIV coinfection

CROI: Etravirine (TMC125) and darunavir (TMC114) in treatment-experienced patients

Receive the latest HIV research and conference news

Showing "11155" results for ""

CROI: Atazanavir/ritonavir joins other boosted PIs as potential single-class maintenance regimen

CROI: HIV subtype D causes disease more rapidly than HIV-1 subtype A in Uganda

CROI: CD4-guided treatment interruptions unsafe, SMART study concludes

CROI: Merck integrase inhibitor strong in highly treatment-experienced patients

CROI: Side-effects, especially neuropathy and rash, common but rarely severe in two studies of African patients on antiretroviral therapy

CROI: New Gilead integrase inhibitor GS-9137 displays potent activity

CROI: Heart attack risk elevated by protease inhibitor treatment but not NNRTIs

CROI: Tenofovir and kidney toxicity - low rates seen, but some groups may be more vulnerable

CROI News Feature: Experts divided over the future of treatment interruptions

CROI: Study reveals widespread misunderstandings about post-exposure prophylaxis among US doctors

CROI: Greater declines in TB incidence observed with long-term antiretroviral therapy

CROI: Study fuels debate on role of GB virus C in HIV disease

CROI: Capsaicin patch helps relieve neuropathy

CROI: Fish oil and fibrate combination reduces blood fats in HIV patients

CROI: Disappointment for glitazones, metformin and testosterone for body fat changes

CROI: Risk of new illnesses declines sharply after first two months on treatment in resource-limited settings

CROI: TB rates skyrocketing in Western Cape township — most infectious cases associated with HIV coinfection

CROI: Etravirine (TMC125) and darunavir (TMC114) in treatment-experienced patients

Receive the latest HIV research and conference news